<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02653105</url>
  </required_header>
  <id_info>
    <org_study_id>ICO-A-2014-05</org_study_id>
    <secondary_id>2014-A00305-42</secondary_id>
    <nct_id>NCT02653105</nct_id>
  </id_info>
  <brief_title>Women at Risk of Breast Cancer and OLFM4</brief_title>
  <official_title>Evaluation of the Circulating Concentration of Olfactomédine 4 (OLFM4) in Women With a BRCA1 or 2 Gene Mutation or at High Risk of Developing Breast Cancer, According to the Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Cancerologie de l'Ouest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Cancerologie de l'Ouest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Does the olfactomédine provide an help to limit the number of false positives in the overall
      imaging balance and limit the number of unnecessary biopsies?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      About 5% of breast cancers are associated with the presence of a constitutional genetic
      alteration. Two genes are being studied: BRCA1 and BRCA2.

      The national program for breast cancer screening target women 50 to 74 years but does not
      include women with significant risk factors. However in identifiable risk situations, breast
      cancer incidence is increased: and it affects 1 in 4 women with certain risk histological
      lesions and more than 1 in 2 women carrying a mutation in the BRCA1 or BRCA2 gene.

      Studies have shown that the olfactomédine 4 (OLFM4) is highly overexpressed in tumors
      compared to healthy tissue. The OLFM4 might therefore be a marker for early detection of
      breast cancer. We wish to determine the positive predictive value of OLFM4 seric dosing of
      patients at risk with respect to imaging.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">February 2026</completion_date>
  <primary_completion_date type="Anticipated">February 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The OLFM4 rate will be dosing by ELISA test in initial and followed blood sample of patient. This rate will be compared to the imaging to determine the positive predictive value of the assay OLFM4</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The OLFM4 rate will be dosing by ELISA test in initial and followed blood sample of patient. This rate will be compared to the histology when it's possible.</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Hereditary Breast and Ovarian Cancer Syndrome</condition>
  <arm_group>
    <arm_group_label>OLFM4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient have a blood test every 6 months at the same time of the clinical exam planned in the following. The OLFM4 will be dose in the blood sample and the rate of OLFM4 compared to the result of imaging.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>OLFM4</intervention_name>
    <description>patient have an additional blood test every 6 months for dosing OLFM4</description>
    <arm_group_label>OLFM4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; or = 18 years

          -  High risk women of breast cancer occurrence defined by the following criteria:

               -  Women carrying a genetic mutation BRCA1 or 2 or TP53, entering or already in
                  screening breast IRM

               -  Women with a high probability of hereditary predisposition to breast cancer (20%
                  risk at 70 years of breast cancer by BOADICEA model), assessed by the
                  onco-geneticists

          -  Information of the person and signing the informed consent

        Exclusion Criteria:

          -  Women with a history of breast cancer or in situ

          -  Person who is not affiliated to a social security scheme or beneficiary of such a
             regime
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paule AUGEREAU, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de l'Ouest - ANGERS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Magali BALAVOINE</last_name>
    <phone>2 41 35 29 31</phone>
    <phone_ext>00 33</phone_ext>
    <email>magali.balavoine@ico.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>François PEIN, MD</last_name>
    <phone>2 40 67 99 08</phone>
    <phone_ext>00 33</phone_ext>
    <email>francois.pein@ico.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Cancerologie de l'Ouest</name>
      <address>
        <city>Angers</city>
        <zip>49055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paule AUGEREAU, MD</last_name>
      <email>paule.augereau@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Paule AUGEREAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Séverine AUDEBERT-BELLANGER, MD</last_name>
      <email>severine.audebert@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Séverine AUDEBERT-BELLANGER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Cholet</city>
        <zip>49300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier INGSTER, MD</last_name>
      <email>olivier.ingster@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier INGSTER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instit de Cancérologie de l'Ouest</name>
      <address>
        <city>Nantes</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Capucine DELNATTE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Capucine DELNATTE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU La Mileterie</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brigitte GILBERT-DUSSARDIER, MD, PhD</last_name>
      <email>brigitte.gibert-dussardier@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Brigitte GIBERT-DUSSARDIER, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle MORTEMOUSQUE, MD</last_name>
      <email>i.mortemousque@chu-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle MORTEMOUSQUE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHBA Hopital Chubert</name>
      <address>
        <city>Vannes</city>
        <zip>56000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hubert JOURNEL, MD</last_name>
      <email>hubert.journel@ch-bretagne-atlantique.fr</email>
    </contact>
    <investigator>
      <last_name>Hubert JOURNEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2016</study_first_submitted>
  <study_first_submitted_qc>January 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2016</study_first_posted>
  <last_update_submitted>January 11, 2016</last_update_submitted>
  <last_update_submitted_qc>January 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High risk of cancer, BRCA1 or 2 mutation, Olfactomedine 4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hereditary Breast and Ovarian Cancer Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

